<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>18 patients with severe stabilized pyramidal <z:hpo ids='HP_0001276'>hypertonia</z:hpo> were treated with <z:chebi fb="0" ids="9654">Trazodone</z:chebi> for a minimum period of 60 days with a daily oral dose of 200-300 mg </plain></SENT>
<SENT sid="1" pm="."><plain>The reduction of <z:hpo ids='HP_0001276'>hypertonia</z:hpo> was assessed using the Ashworth Scale to evaluate symptoms and signs </plain></SENT>
<SENT sid="2" pm="."><plain>On the whole 12 patients showed a clinical improvement; eight of them showed an improvement of at least 2 items on the Ashworth Scale </plain></SENT>
<SENT sid="3" pm="."><plain>The reduction of <z:hpo ids='HP_0001276'>hypertonia</z:hpo> began on the 4-5th day of therapy, progressing until the 10-12th day of treatment and then remained constant </plain></SENT>
<SENT sid="4" pm="."><plain>Tolerance was very good </plain></SENT>
<SENT sid="5" pm="."><plain>Despite the low number of patients in the study the authors obtained good results suggesting that <z:chebi fb="0" ids="9654">Trazodone</z:chebi> should be studied further in this field </plain></SENT>
</text></document>